Apellis Pharmaceuticals IPO

11/9/2017

IPO

$149,800,000

We currently estimate that we will use the net proceeds from this offering, together with our existing cash and cash equivalents, including the net proceeds from our sale of shares of series E convertible preferred stock and our borrowings under our $20.0 million term loan facility with Silicon Valley Bank and a $7.0 million promissory note issued to an affiliate of one of our stockholders, as follows: approximately $48.0 million to $59.0 million for our ongoing and planned clinical trials of APL-2 in patients with GA and wet AMD; approximately $47.0 million to $58.0 million for our ongoing and planned clinical trials of APL-2 in patients with PNH; approximately $43.0 million to $53.0 million for our other planned clinical trials of APL-2 and development of new product candidates; and the remainder for working capital and other general corporate purposes.

Publicly-held

Biopharmaceutical

6400 Westwind Way A
Crestwood, KY 40014
USA

Apellis (NASDAQ: APLS) was founded in 2009. Apellis' approach is centered on the inhibition of the complement system, which is a cascade of interacting proteins and is an integral component of the immune system.